H3ABioNet Seminars' Series
The H3ABioNet Seminar coordinators and task force cordially invite you to join us for our tenth webinar for 2022, the November seminar titled "Implementation of clinical Whole Genome Sequencing across the sea".
Seminar Format: A seminar talk will be provided by Dr Aimé Lumaka, a Professor of Genetics and Pediatrics at the University of Kinshasa (DR Congo), the Coordinator of a Genomic Medicine platform at the University of Liège (Belgium). This intriguing talk will be 40 to 50 minutes long followed by 10 to 15 minutes of Questions & Answer as well as Discussion.
Seminar Date: Wednesday, 16 November 2022
Seminar time: 8am EST/ 5am PDT / 1pm UTC / 3pm CET/ 2pm WAT /2pm LT/ 3pm CAT / 4pm EAT
URL to join the seminar: https://tinyurl.com/webinar1611
Previous H3ABioNet seminars are available on YouTube
**********************************************************************************
Dr Aimé Lumaka
Dr Aimé Lumaka graduated from the Medical school (2005) and specialized in Pediatrics (2012) at the University of Kinshasa (DR Congo). He later obtained his PhD degree in Human Genetics and Genomics at the KU Leuven (Belgium). After working for 2 years in a genome interpretation company, he joined the University of Liège in 2018. Dr Lumaka is Professor of Genetics and Pediatrics at the University of Kinshasa (DR Congo), the Coordinator of a Genomic Medicine platform at the University of Liège (Belgium).
His current work focuses on the use of Whole Genome Sequencing as the tool to foster the identification of novel rare diseases genes and improve care for rare diseases patients, especially in resource-limited countries. Dr Lumaka is currently a clinical consultant in genetics at the University hospitals of Liège (Belgium), the chair of the Rare Diseases Working Group of the H3-Africa consortium and the Director of the Reference Center for Rare and Undiagnosed Diseases in the RD Congo. His contributions to science also include the (1) identification of genetic anomalies causing developmental diseases in African patients, (2) description of African phenotype in known genetic diseases and (3) identification of genetic modifiers of the phenotype and treatment response in Sickle Cell Anemia.